Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Has $10.09 Million Stake in Scholar Rock Holding Corporation (NASDAQ:SRRK)

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. decreased its position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 18.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 313,689 shares of the company's stock after selling 72,236 shares during the period. Scholar Rock makes up approximately 2.0% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s holdings, making the stock its 18th largest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned approximately 0.33% of Scholar Rock worth $10,085,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SRRK. FMR LLC boosted its position in Scholar Rock by 33.7% in the fourth quarter. FMR LLC now owns 13,635,261 shares of the company's stock worth $589,316,000 after purchasing an additional 3,439,215 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Scholar Rock by 1,283.7% in the fourth quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock worth $127,301,000 after acquiring an additional 2,732,546 shares during the period. Norges Bank purchased a new stake in shares of Scholar Rock during the fourth quarter worth about $86,043,000. Fairmount Funds Management LLC purchased a new position in Scholar Rock in the 4th quarter worth approximately $84,839,000. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in Scholar Rock during the 4th quarter valued at approximately $68,930,000. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Akshay Vaishnaw sold 6,750 shares of the company's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $29.72, for a total transaction of $200,610.00. Following the completion of the transaction, the insider owned 616,205 shares in the company, valued at approximately $18,313,612.60. This represents a 1.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Joshua Reed sold 5,400 shares of the business's stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $29.72, for a total value of $160,488.00. Following the transaction, the director owned 15,732 shares in the company, valued at $467,555.04. The trade was a 25.55% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 93,654 shares of company stock valued at $3,101,811 over the last quarter. Insiders own 13.30% of the company's stock.

Scholar Rock Price Performance

NASDAQ SRRK traded down $0.54 during trading hours on Friday, reaching $38.57. The company's stock had a trading volume of 352,312 shares, compared to its average volume of 1,177,391. The company's 50-day moving average is $34.28 and its two-hundred day moving average is $35.04. Scholar Rock Holding Corporation has a 1-year low of $6.76 and a 1-year high of $46.98. The firm has a market capitalization of $3.66 billion, a price-to-earnings ratio of -15.25 and a beta of 0.33. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.25 and a quick ratio of 10.25.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same period last year, the business earned ($0.59) earnings per share. On average, equities analysts predict that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SRRK. Cantor Fitzgerald began coverage on shares of Scholar Rock in a report on Thursday, July 17th. They issued an "overweight" rating on the stock. Lifesci Capital raised shares of Scholar Rock to a "strong-buy" rating in a research report on Tuesday, June 3rd. Finally, Wedbush restated an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Wednesday, June 18th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Scholar Rock has a consensus rating of "Buy" and an average target price of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.